| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, University Hospital Essen, Germany.
Address correspondence and reprint requests to Dr. Hans-Christoph Diener, Department of Neurology, University Hospital Essen, University of Essen, Hufelandstr. 55, 45122 Essen, Germany; e-mail: h.diener{at}uni-essen.de
Objective: To investigate pharmacologic features such as mean critical duration until onset of medication-overuse headache (MOH) (MCDO), mean critical monthly intake frequencies (MCMIF), and mean critical monthly dosages (MCMD) as well as specific clinical features of MOH after overuse of different acute headache drugs, with a focus on newly approved triptans.
Methods: In a prospective study 98 patients with MOH according to International Headache Society (IHS) criteria underwent standardized inpatient withdrawal from their medication. Patient diaries and structured interviews were used to calculate the MCDO, MCMIF, and MCMD for each substance group.
Results: The MCDO was shortest for triptans (1.7 years), longer for ergots (2.7 years), and longest for analgesics (4.8 years). The MCMIF was lowest for triptans (18 single doses per month), higher for ergots (37), and highest for analgesics (114). Although patients overusing ergots and analgesics typically had a daily tension-type headache, patients with triptan-induced MOH were more likely to describe a (daily) migrainelike headache or an increase in migraine frequency.
Conclusion: Overuse of triptans leads to MOH faster and with lower dosages compared with ergots and analgesics. Clinical features of MOH depend on the type of overused headache medication. Pharmacologic and clinical characteristics of triptan-induced MOH call for the renewal of the current IHS classification.
This article has been cited by other articles:
|
|
 |
|
  M. G. Boe, A. Mygland, and R. Salvesen Prednisolone does not reduce withdrawal headache: A randomized, double-blind study Neurology, July 3, 2007; 69(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.V.S. Lakshmi, P. Singhi, P. Malhi, and M. Ray Topiramate in the Prophylaxis of Pediatric Migraine: A Double-Blind Placebo-Controlled Trial J Child Neurol, July 1, 2007; 22(7): 829 - 835. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Tucker A Practical Approach to Headache Treatment Journal of Pharmacy Practice, April 1, 2007; 20(2): 123 - 136. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Fuller and C. Kaye Headaches BMJ, February 3, 2007; 334(7587): 254 - 256. [Full Text] [PDF]
|
|
|
|
|
|
K. Paemeleire, A. Bahra, S. Evers, M. S. Matharu, and P. J. Goadsby Medication-overuse headache in patients with cluster headache. Neurology, July 11, 2006; 67(1): 109 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fumal, R. Kupers, and J. Schoenen Reply: Orbitofrontal cortex hypometabolism, medication overuse headache, substance abuse and migraine: key pathophysiological issues Brain, July 1, 2006; 129(7): E53 - E53. [Full Text] [PDF]
|
|
|
|
|
|
P. Zeeberg, J. Olesen, and R. Jensen Probable medication-overuse headache: The effect of a 2-month drug-free period Neurology, June 27, 2006; 66(12): 1894 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fumal, S. Laureys, L. Di Clemente, M. Boly, V. Bohotin, M. Vandenheede, G. Coppola, E. Salmon, R. Kupers, and J. Schoenen Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine Brain, February 1, 2006; 129(2): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dyb, T. L. Holmen, and J.-A. Zwart Analgesic overuse among adolescents with headache: The Head-HUNT-Youth Study Neurology, January 24, 2006; 66(2): 198 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Silberstein Chronic Daily Headache J Am Osteopath Assoc, April 1, 2005; 105(4_suppl): 23S - 29S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. -A. Zwart, G. Dyb, K. Hagen, S. Svebak, L. J. Stovner, and J. Holmen Analgesic overuse among subjects with headache, neck, and low-back pain Neurology, May 11, 2004; 62(9): 1540 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Katsarava, S. Schneeweiss, T. Kurth, U. Kroener, G. Fritsche, A. Eikermann, H. -C. Diener, and V. Limmroth Incidence and predictors for chronicity of headache in patients with episodic migraine Neurology, March 9, 2004; 62(5): 788 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Brandes, J. R. Saper, M. Diamond, J. R. Couch, D. W. Lewis, J. Schmitt, W. Neto, S. Schwabe, and D. Jacobs Topiramate for Migraine Prevention: A Randomized Controlled Trial JAMA, February 25, 2004; 291(8): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
December 23 Highlight and Commentary Neurology, December 23, 2003; 61(12): 1637 - 1637. [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, October 6, 2003; 327(7418): E178 - 178. [Full Text] [PDF]
|
|
|
|
|
|
J.-A. Zwart, G. Dyb, K. Hagen, S. Svebak, and J. Holmen Analgesic use: A predictor of chronic pain and medication overuse headache: The Head-HUNT Study Neurology, July 22, 2003; 61(2): 160 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Katsarava, V. Limmroth, M. Finke, H. C. Diener, and G. Fritsche Rates and predictors for relapse in medication overuse headache: A 1-year prospective study Neurology, May 27, 2003; 60(10): 1682 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Minerva BMJ, October 19, 2002; 325(7369): 912 - 912. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Silberstein and K.M.A. Welch Painkiller headache Neurology, October 8, 2002; 59(7): 972 - 974. [Full Text] [PDF]
|
|
|
|
|
|
G. Dyb, T. L. Holmen, and J.-A. Zwart Analgesic overuse among adolescents with headache: The Head-HUNT-Youth Study Neurology, January 24, 2006; 66(2): 198 - 201. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
